Transcriptional Regulation of Genetic Variants in the Promoter

Overview

Journal Korean J Physiol Pharmacol

Specialty Pharmacology

Date 2024 Feb 28

PMID 38414394

Authors

Seung Yeon Ha

Jin-Young Kim

Ji Ha Choi

Affiliations

Soon will be listed here.

Abstract

encodes ferroportin, which is the only known transmembrane protein that exports elemental iron from mammalian cells and is essential for iron homeostasis. Mutations in are associated with iron-overload disorders. In addition to ferroportin diseases, expression is downregulated in various cancer types. Despite the clinical significance of the SLC40A1 transporter, only a few studies have investigated genetic variants in . The present study was performed to identify genetic variations in the promoter and functionally characterize each variant using assays. We investigated four haplotypes and five variants in the promoter. We observed that haplotype 3 (H3) had significantly lower promoter activity than H1, whereas the activity of H4 was significantly higher than that of H1. Luciferase activity of H2 was comparable to that of H1. In addition, four variants of , c.-1355G>C, c.-662C>T, c.-98G>C, and c.-8C>G, showed significantly increased luciferase activity compared to the wild type (WT), whereas c.-750G>A showed significantly decreased luciferase activity compared to the WT. Three transcription factors, cAMP response element-binding protein-1 (CREB-1), chicken ovalbumin upstream promoter transcription factor 1, and hepatic leukemia factor (HLF), were predicted to bind to the promoter regions of near c.-662C>T, c.-98G>C, and c.-8C>G, respectively. Among these, CREB-1 and HLF bound more strongly to the variant sequences than to the WT and functioned as activators of transcription. Collectively, our findings indicate that the two promoter haplotypes affect transcription, which is regulated by CREB-1 and HLF.

References

Cooper-DeHoff R, Niemi M, Ramsey L, Luzum J, Tarkiainen E, Straka R . The Clinical Pharmacogenetics Implementation Consortium Guideline for SLCO1B1, ABCG2, and CYP2C9 genotypes and Statin-Associated Musculoskeletal Symptoms. Clin Pharmacol Ther. 2022; 111(5):1007-1021. PMC: 9035072. DOI: 10.1002/cpt.2557. View

Xue D, Zhou C, Shi Y, Lu H, He X . Decreased expression of ferroportin in prostate cancer. Oncol Lett. 2015; 10(2):913-916. PMC: 4509077. DOI: 10.3892/ol.2015.3363. View

Lelievre P, Sancey L, Coll J, Deniaud A, Busser B . Iron Dysregulation in Human Cancer: Altered Metabolism, Biomarkers for Diagnosis, Prognosis, Monitoring and Rationale for Therapy. Cancers (Basel). 2020; 12(12). PMC: 7761132. DOI: 10.3390/cancers12123524. View

Nabokina S, Ramos M, Valle J, Said H . Regulation of basal promoter activity of the human thiamine pyrophosphate transporter SLC44A4 in human intestinal epithelial cells. Am J Physiol Cell Physiol. 2015; 308(9):C750-7. PMC: 4420793. DOI: 10.1152/ajpcell.00381.2014. View

Waters K, Sontag R, Weber T . Hepatic leukemia factor promotes resistance to cell death: implications for therapeutics and chronotherapy. Toxicol Appl Pharmacol. 2013; 268(2):141-8. DOI: 10.1016/j.taap.2013.01.031. View

Fischer S, Schmidt K, Fiedler N, Glebe D, Schuttler C, Sun J . Genotype-dependent activation or repression of HBV enhancer II by transcription factor COUP-TF1. World J Gastroenterol. 2006; 12(37):6054-8. PMC: 4124418. DOI: 10.3748/wjg.v12.i37.6054. View

Xin Z, Hu H, Lao Z, Zhu L, Biskup E, Zhang H . p-CREB-1 at Ser 133 is a potential marker for breast cancer. Eur Rev Med Pharmacol Sci. 2020; 24(22):11628-11638. DOI: 10.26355/eurrev_202011_23806. View

Leung E, Hong J, Fraser A, Merriman T, Vishnu P, Krissansen G . Polymorphisms in the organic cation transporter genes SLC22A4 and SLC22A5 and Crohn's disease in a New Zealand Caucasian cohort. Immunol Cell Biol. 2006; 84(2):233-6. DOI: 10.1111/j.1440-1711.2006.01423.x. View

Wahlestedt M, Ladopoulos V, Hidalgo I, Sanchez Castillo M, Hannah R, Sawen P . Critical Modulation of Hematopoietic Lineage Fate by Hepatic Leukemia Factor. Cell Rep. 2017; 21(8):2251-2263. PMC: 5714592. DOI: 10.1016/j.celrep.2017.10.112. View

10.

Detivaud L, Island M, Jouanolle A, Ropert M, Bardou-Jacquet E, Le Lan C . Ferroportin diseases: functional studies, a link between genetic and clinical phenotype. Hum Mutat. 2013; 34(11):1529-36. DOI: 10.1002/humu.22396. View

11.

Moreno-Carralero M, Munoz-Munoz J, Cuadrado-Grande N, Lopez-Rodriguez R, Jose Hernandez-Alfaro M, del-Castillo-Rueda A . A novel mutation in the SLC40A1 gene associated with reduced iron export in vitro. Am J Hematol. 2014; 89(7):689-94. DOI: 10.1002/ajh.23714. View

12.

Kim B, Song H, Kim J, Kwon E, Ha S, Kim M . Functional characterization of ABCA4 genetic variants related to Stargardt disease. Sci Rep. 2022; 12(1):22282. PMC: 9790013. DOI: 10.1038/s41598-022-26912-6. View

13.

Park H, Jung E, Kong K, Park E, Cheon J, Choi J . Identification of OCTN2 variants and their association with phenotypes of Crohn's disease in a Korean population. Sci Rep. 2016; 6:22887. PMC: 4786794. DOI: 10.1038/srep22887. View

14.

Xiang D, Sun W, Ning B, Zhou T, Li X, Zhong W . The HLF/IL-6/STAT3 feedforward circuit drives hepatic stellate cell activation to promote liver fibrosis. Gut. 2017; 67(9):1704-1715. DOI: 10.1136/gutjnl-2016-313392. View

15.

Martinez A, Del Carmen Martin M, Mendoza J, Taxonera C, Diaz-Rubio M, de la Concha E . Association of the organic cation transporter OCTN genes with Crohn's disease in the Spanish population. Eur J Hum Genet. 2005; 14(2):222-6. DOI: 10.1038/sj.ejhg.5201529. View

16.

Ravasi G, Pelucchi S, Russo A, Mariani R, Piperno A . Ferroportin disease: A novel SLC40A1 mutation. Dig Liver Dis. 2020; 52(6):688-690. DOI: 10.1016/j.dld.2020.03.013. View

17.

Wu J, Zhang L, Wu S, Yi X, Liu Z . miR-194-5p inhibits SLC40A1 expression to induce cisplatin resistance in ovarian cancer. Pathol Res Pract. 2020; 216(7):152979. DOI: 10.1016/j.prp.2020.152979. View

18.

Vivot A, Boutron I, Ravaud P, Porcher R . Guidance for pharmacogenomic biomarker testing in labels of FDA-approved drugs. Genet Med. 2014; 17(9):733-8. DOI: 10.1038/gim.2014.181. View

19.

Deng L, Huang L, Guo Q, Shi X, Xu K . CREB1 and Smad3 mediate TGF‑β3‑induced Smad7 expression in rat hepatic stellate cells. Mol Med Rep. 2017; 16(6):8455-8462. DOI: 10.3892/mmr.2017.7654. View

20.

Rodriguez-Tirado C, Kale N, Carlini M, Shrivastava N, Rodrigues A, Khalil B . NR2F1 Is a Barrier to Dissemination of Early-Stage Breast Cancer Cells. Cancer Res. 2022; 82(12):2313-2326. PMC: 9203932. DOI: 10.1158/0008-5472.CAN-21-4145. View